4.97
Alumis Inc (ALMS) 最新ニュース
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Alumis stock price target cut to $14 by H.C. Wainwright - Investing.com India
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis And Acelyrin Announce Amended Merger Agreement - marketscreener.com
Alumis, ACELYRIN amend proposed merger pact - Seeking Alpha
Alumis Raises Share Consideration for Acelyrin Acquisition - marketscreener.com
ACELYRIN, INC. Amends Merger Agreement with Alumis - TipRanks
ACELYRIN and Alumis Announce Revised Merger Agreement Enhancing Stockholder Ownership and Value - Nasdaq
Alumis and ACELYRIN Announce Amended Merger Agreement - The Manila Times
Alumis Secures Major Immunology Merger: $737M Cash Runway Stretches to 2027, 62% Shareholders Back Deal - Stock Titan
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Benzinga
3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis: Biotech's Stock Gains >100% In A MonthBut Risk Of Failure Is High (NASDAQ:ALMS) - Seeking Alpha
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying - simplywall.st
Insider Buying: Alumis Independent Director Bought US$130k Of Shares - Yahoo
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
Simulations Plus Posts Better-Than-Expected Results, Joins Savers Value Village, MarketAxess Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Alumis Inc. CEO Martin Babler buys $100,732 in company stock By Investing.com - Investing.com Australia
Alumis Inc. director Alan Colowick buys $129,544 in stock By Investing.com - Investing.com Australia
Top Executives Make Bold Moves with Alumis Inc. Stock Purchases! - TipRanks
Alumis Inc. CEO Martin Babler buys $100,732 in company stock - Investing.com
Alumis Inc. director Alan Colowick buys $129,544 in stock - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday - Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Alumis Inc. (NASDAQ:ALMS) Stock Holdings Increased by Charles Schwab Investment Management Inc. - Defense World
Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs - MarketBeat
The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter
Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars - insights.citeline.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph
Alumis and Kaken Pharma announce collaboration worth $140 M for dermatology treatment in Japan - BioSpectrum Asia
Alumis Inc. Reports 2024 Results and Strategic Merger - TipRanks
Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc. - TipRanks
Alumis stock holds $15 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Alumis stock holds $15 target, Buy rating at H.C. Wainwright - Investing.com
Q1 Earnings Forecast for Alumis Issued By Leerink Partnrs - Defense World
Alumis sees uptick as Kaken locks Japan rights for dermatology asset - FirstWord Pharma
Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire
大文字化:
|
ボリューム (24 時間):